Daniel C Andersson

Dr. Daniel C Andersson

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2011 in Cell Metabolism
Verified
Journal Article
Closed access
DADaniel C Andersson
Daniel C Andersson
MBMatthew J. Betzenhauser
Matthew J. Betzenhauser
SRSteven Reiken
Steven Reiken
AMAlbano Meli
Albano Meli
AUAlisa Umanskaya
Alisa Umanskaya
AMAndrew R. Marks
Andrew R. Marks

12 October 2015 in Nature Medicine
Verified
Journal Article
Open access
PDF file
DWDavid L Waning
David L Waning
KMKhalid S Mohammad
Khalid S Mohammad
SRSteven Reiken
Steven Reiken
WXWenjun Xie
Wenjun Xie
DADaniel C Andersson
Daniel C Andersson
TGTheresa A Guise
Theresa A Guise
Metastasis-mediated osteolysis results in excess release of TGF-β that, in turn, leads to muscle weakness. Cancer-associated muscle weakness is a poorly understood phenomenon, and there is no effective treatment. Here we find that seven different mouse models of human osteolytic bone metastases—representing breast, lung and prostate cancers, as well as multiple myeloma—exhibited impaired muscle function, implicating a role for the tumor-bone microenvironment in cancer-associated muscle weakness. We found that transforming growth factor (TGF)-β, released from the bone surface as a result of metastasis-induced bone destruction, upregulated NADPH oxidase 4 (Nox4), resulting in elevated oxidization of skeletal muscle proteins, including the ryanodine receptor and calcium (Ca2+) release channel (RyR1). The oxidized RyR1 channels leaked Ca2+, resulting in lower intracellular signaling, which is required for proper muscle contraction. We found that inhibiting RyR1 leakage, TGF-β signaling, TGF-β release from bone or Nox4 activity improved muscle function in mice with MDA-MB-231 bone metastases. Humans with breast- or lung cancer–associated bone metastases also had oxidized skeletal muscle RyR1 that is not seen in normal muscle. Similarly, skeletal muscle weakness, increased Nox4 binding to RyR1 and oxidation of RyR1 were present in a mouse model of Camurati-Engelmann disease, a nonmalignant metabolic bone disorder associated with increased TGF-β activity. Thus, pathological TGF-β release from bone contributes to muscle weakness by decreasing Ca2+-induced muscle force production.

1 August 2018 in JACC
Verified
Journal Article
Closed access
ZZZhichao Zhou
Zhichao Zhou
AMAli Mahdi
Ali Mahdi
YTYahor Tratsiakovich
Yahor Tratsiakovich
SZSzabolcs Zahorán
Szabolcs Zahorán
OKOskar Kövamees
Oskar Kövamees
JPJohn Pernow
John Pernow

15 May 2016 in American Journal of Physiology-Cell Physiology
Verified
Journal Article
Closed access
PDF file
MSMaja Schlittler
Maja Schlittler
MGMichel Goiny
Michel Goiny
LALeandro Z. Agudelo
Leandro Z. Agudelo
TVTomas Venckunas
Tomas Venckunas
MBMarius Brazaitis
Marius Brazaitis
DADaniel C Andersson
Daniel C Andersson
Physical exercise has emerged as an alternative treatment for patients with depressive disorder. Recent animal studies show that exercise protects from depression by increased skeletal muscle kynurenine aminotransferase (KAT) expression which shifts the kynurenine metabolism away from the neurotoxic kynurenine (KYN) to the production of kynurenic acid (KYNA). In the present study, we investigated the effect of exercise on kynurenine metabolism in humans. KAT gene and protein expression was increased in the muscles of endurance-trained subjects compared with untrained subjects. Endurance exercise caused an increase in plasma KYNA within the first hour after exercise. In contrast, a bout of high-intensity eccentric exercise did not lead to increased plasma KYNA concentration. Our results show that regular endurance exercise causes adaptations in kynurenine metabolism which can have implications for exercise recommendations for patients with depressive disorder.

1 March 2017 in JACC
Verified
Journal Article
Closed access
ÄMÄngla Mantel
Ängla Mantel
MHMarie Holmqvist
Marie Holmqvist
DADaniel C Andersson
Daniel C Andersson
LLLars H. Lund
Lars H. Lund
JAJohan Askling
Johan Askling

6 October 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
AUAlisa Umanskaya
Alisa Umanskaya
Gaetano SantulliGaetano Santulli
Gaetano Santulli
WXWenjun Xie
Wenjun Xie
DADaniel C Andersson
Daniel C Andersson
SRSteven R. Reiken
Steven R. Reiken
AMAndrew R. Marks
Andrew R. Marks
Age-related skeletal muscle dysfunction is a leading cause of morbidity that affects up to half the population aged 80 or greater. Here we tested the effects of increased mitochondrial antioxidant activity on age-dependent skeletal muscle dysfunction using transgenic mice with targeted overexpression of the human catalase gene to mitochondria (MCat mice). Aged MCat mice exhibited improved voluntary exercise, increased skeletal muscle specific force and tetanic Ca2+ transients, decreased intracellular Ca2+ leak and increased sarcoplasmic reticulum (SR) Ca2+ load compared with age-matched wild type (WT) littermates. Furthermore, ryanodine receptor 1 (the sarcoplasmic reticulum Ca2+ release channel required for skeletal muscle contraction; RyR1) from aged MCat mice was less oxidized, depleted of the channel stabilizing subunit, calstabin1, and displayed increased single channel open probability (Po). Overall, these data indicate a direct role for mitochondrial free radicals in promoting the pathological intracellular Ca2+ leak that underlies age-dependent loss of skeletal muscle function. This study harbors implications for the development of novel therapeutic strategies, including mitochondria-targeted antioxidants for treatment of mitochondrial myopathies and other healthspan-limiting disorders.